The leading digital innovator for proven advanced therapy solutions
Provider of the proven clinical-to-commercial platform for cell and gene therapy supply chain management.
Vineti is a place where leaders enterprise software and the life sciences have collaborated to deliver safety, security, seamlessness, and scalability to advance therapy supply chains. We are an expert team with decades of collective experience in healthcare systems, cloud-based software development, and logistics and have developed patented technology for personalized therapeutics. We are dedicated to solving key challenges in cell and gene therapies through purpose-built enterprise software. Vineti’s platform connects the right patient to the right therapeutic product, on time and on track.
We are passionately committed to the success of breakthrough cell and gene therapies to shape the lives of millions of patients. Our customers are the heroic providers of these revolutionary new treatments, addressing a wide range of serious health conditions, from cancer to rare genetic disorders.
We believe the promise of cell and gene therapies is here — right now — and nobody is better positioned than Vineti to help forge the right path to get amazing science through the clinic, over the finish line, and accelerate access to patients in need.
We understand that medicine’s most complex supply chain requires a state-of-the-art, modern enterprise software solution to quickly, safely, securely, and seamlessly move these amazing medicines forward. We owe it to our customers — and in turn, the patients they serve — to deliver unparalleled systems to make this possible.
From the beginning, we have been passionate about developing cloud-based enterprise solutions to improve access to life-changing advanced therapies.
At the request of a leading biopharmaceutical innovator, experts from GE Ventures and Mayo Clinic come together to envision new technologies for the patient journey in the emerging ecosystem of cell therapies, gene therapies, and personalized cancer vaccines. “Vitruvian Networks” is launched to develop a compliant, validated, scalable digital solution to support the new landscape of personalized therapy workflows. The company announces its first strategic biopharmaceutical collaboration with CAR-T cell therapy pioneer Kite Pharma.
Vitruvian Networks becomes Vineti. The name derives from an ancient word that evokes progress through the elimination of obstacles. The Vineti solution goes live as the first independent system of its kind to support patients receiving a commercially-approved CAR-T cell therapy. The company closes a $33.5M Series B round of funding with top-tier investors including Canaan, Threshold Ventures (formerly DFJ), and Section 32.
The World Economic Forum selects Vineti for its prestigious Technology Pioneer honor, as a company with the potential to “improve society for years to come." The company opens a new regional headquarters in Bethesda, Maryland, and announces a series of key industry alliances, including Cryoport, Lonza, and Wuxi AppTec. An op-ed in STAT News makes the case for the "industrialization of personalization" to scale advance therapies.
Vineti extends Series C funding through an expanded investor coalition, raising more than $115 million to date from top-tier investors, including Cardinal Health, Casdin Capital, and Marc Benioff. Despite the challenges of the COVID-19 pandemic, the company continues to grow, expanding to more than 150 team members, launching a new set of flexibility features to support cell and gene therapies, and releasing a proposal for a new patient ID for personalized medicine.
Vineti continues to help to break down barriers to the advancement of personalized therapeutics with its PTMR enterprise platform. The company expands to more than 180 team members, and launches its PTM EssentialsTM solution for clinical-phase advanced therapies. Vineti's technology continues to expand to support advanced therapies for patients at hundreds of clinical sites in more than 20 countries.